Immune response to pneumococcal conjugate vaccination in asplenic individuals

Human Vaccines

Volumn 5, Issue 2, 2009, Pages 85-91

  Stanford, Elaine ^a   Print, Fiona ^b   Falconer, Michelle ^c   Lamden, Kenneth ^b   Ghebrehewet, Samuel ^c   Phin, Nick ^a   Baxter, David ^d   Helbert, Matthew ^e   McCann, Rosemary ^f   Andrews, Nick ^a   Balmer, Paul ^a   Borrow, Ray ^a   Kaczmarski, Edward ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Central Lancashire Primary Care Trust   (United Kingdom)

^c Chester Microbiology Laboratory   (United Kingdom)

^d Infection Control Unit   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f Greater Manchester Health Protection Unit   (United Kingdom)

Author keywords

Asplenic; Conjugate vaccine; Immunization; Pneumococcal; Polysaccharide vaccine

Indexed keywords

ACT HIB; ANTIBIOTIC AGENT; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOVAX 2; PRENAVER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; ASPLENIA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; SEROTYPING; SINGLE DRUG DOSE; SPLENECTOMY; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GREAT BRITAIN; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 67549120068     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.2.6557     Document Type: Article

References (26)

1. Shatz DV. Vaccination considerations in the asplenic patient. Expert Rev Vaccines 2005; 4:27-34.
2. Department of Health U.K. Immunisation against infectious diseases - "The Green Book". Salisbury D, Ramsay M, Noakes K, editors. TSO 2006; Third Edition. http://www.dh.gov.uk/ PolicyAndGuidance/HealthAndSocialCareTopics/GreenBook/ GreenBookGeneralInformation/GreenBookGeneralArticle/fs/ en?CONTENT_ID=4097254&chk=isTfGX (last accessed 09/11/07).
3. Davies JM, Barnes R, Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002; 2:440-3.
4. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventative measures are not being followed. J Clin Pathol 2001; 54:214-8.
5. Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 2001; 7:657-60.
6. Giebink GS, Le CT, Cosio FG, Spika JS, Schiffman G. Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 1981; 3:168-78.
7. Rytel MW, Dailey MP, Schiffman G, Hoffmann RG, Piering WF. Pneumococcal vaccine immunization of patients with renal impairment. Proc Soc Exp Biol Med 1982; 182:468-73.
8. Giebink GS, Foker JE, Kim Y, Schiffman G. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis 1980; 141:404-12.
9. Pedersen FK, Nielsen JL, Ellegaard J. Antibody response to pneumococcal vaccine in splenectomized adults and adolescents. Acta Pathol Microbial Scand 1982; 90:257-63.
10. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. and the Northern California Kaiser Permanente Vaccines Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
11. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362:355-61.
12. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139-46.
13. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser 2005; 927:64-98.
14. Balmer P, Borrow R, Findlow J, Warrington R, Frankland S, Waight P, et al. Age-stratified prevalence of pneumococcal serotype-specific IgG in England and its relationship to serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol 14:1451-7.
15. Devaster JM, Leroux-Roels I, Leroux-Roels G, Vandepapeliere P, Horsmans Y, Henckaerts I et al. Inferior humoral response in elderly versus young adults to the 23-valent polysaccharide vaccine. Abstracts of the 5th International Sysposium on Pneumococci and Pneumococcal Diseases. 2 - 6 April 2006. Central Australia: Alice Springs Convention Centre, Alice Springs 2006; 244.
16. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281-8.
17. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996; 173:387-93.
18. Örtqvist Å, Henckaerts I, Hedlund J, Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine 2007; 25:2445-50.
19. Musher DM, Groover JE, Graviss EA, Baughn RE. The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin Infect Dis 1996; 22:165-7.
20. Bernatoniene J, Finn A. Advances in pneumococcal vaccines. Drugs 2005; 65:229-55.
21. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606.
22. Eigenberger K, Sillaber C, Greitbauer M, Herkner H, Wolf H, Graninger W, et al. Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with haematological malignancies or trauma. Wien Klin Wochenschr 2007; 119:228-34.
23. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diag Lab Immunol 2003; 10:514-9.
24. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). http://www.vaccine.uab.edu/ELISA%20Protocol.pdf (last accessed 09/10/07).
25. Quataert SA, Kirch CS, Weidl LJ, Phipps DC, Strohmeyer S, Cimino CO, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, Lot 89-S. Clin Diag Lab Immunol 1995; 2:590-7.
26. Quataert SA, Rittenhouse-Olsen K, Kirch CS, Hu B, Secor S, Strong N, et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, Lot 89-S(F). Clin Diag Lab Immunol 2004; 11:1064-9.